Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
Massachusetts General Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
STORM Therapeutics LTD
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
University of Florida
MedSIR
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
University of Florida
Essen Biotech
Royal Marsden NHS Foundation Trust
Centre Leon Berard
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jazz Pharmaceuticals
Haihe Biopharma Co., Ltd.
University of Iowa
Adcendo ApS
St. Jude Children's Research Hospital
Perspective Therapeutics
M.D. Anderson Cancer Center
Institut Bergonié
Ocellaris Pharma, Inc.
Eli Lilly and Company
Swiss Cancer Institute
Tanabe Pharma America, Inc.
Eli Lilly and Company
National Taiwan University Hospital
Transgene
Turning Point Therapeutics, Inc.
Shasqi, Inc.
ImmVira Pharma Co. Ltd
Hadassah Medical Organization
Sensei Biotherapeutics, Inc.
Lantheus Medical Imaging
Massachusetts General Hospital
Essen Biotech
University of California, Irvine
PharmaMar
Cancer Research UK
OncoC4, Inc.
ImmunoGenesis